Pharmacy Benefits Management

October 20, 2023

FDA Approves Zituvio (sitagliptin) for the Treatment of Adult Patients with Type 2 Diabetes Mellitus

October 20, 2023 - Zydus Lifesciences has announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Zituvio (Sitagliptin) tablets

October 20, 2023

FDA Approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris

October 20, 2023 – Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, have announced that the U.S. Food and Drug Administration

October 19, 2023

FDA Approval for Generic to Votrient

October 19, 2023 - Apotex Corp.; Sun Pharmaceutical Industries, Inc.; Teva Pharmaceuticals USA, Inc., have been approved by the FDA for the use of Pazopanib Hydrochloride Tablets

October 18, 2023

FDA Approves Bimzelx (bimekizumab-bkzx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

October 18, 2023 - UCB, a global biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved BIMZELX ^® (bimekizumab-bkzx)

October 18, 2023

FDA Approves Maxigesic ® IV to be Marketed in the U.S. as Combogesic ® IV (acetaminophen and ibuprofen) for the Management of Pain

October 18, 2023 - Hyloris Pharmaceuticals SA), today announced Maxigesic^® IV has been approved for the relief of mild to moderate pain and for the management

October 18, 2023

FDA Approves Zituvio (sitagliptin) for the Treatment of Adult Patients with Type 2 Diabetes Mellitus

FDA Approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris

FDA Approval for Generic to Votrient

FDA Approves Bimzelx (bimekizumab-bkzx) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

FDA Approves Maxigesic ® IV to be Marketed in the U.S. as Combogesic ® IV (acetaminophen and ibuprofen) for the Management of Pain

FDA Approves Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the Treatment of Presbyopia

FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults

FDA Approves Xphozah (tenapanor) to Reduce Serum Phosphorus in Adults with Chronic Kidney Disease